Filings · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Carlsmed, Inc. announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting. The launch follows a limited market evaluation that began in February 2026. The system leverages the company's AI-enabled software platform to deliver personalized spine fusion solutions, with endorsements from surgeons at University of Colorado and Mayo Clinic.
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $23 to $24.
Filed: 2026-09-30 AccNo: 0001794546-26-000020 Size: 1 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $23 price target.